Navigation Links
Sosei and Vectura Announce Start of Phase II Studies of QVA149 for the Treatment of COPD
Date:11/15/2007

TOKYO, Japan and CHIPPENHAM, England, November 15 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) and Vectura Group plc ("Vectura"; LSE: VEC) announce the start, by Novartis, of a Phase II safety study of QVA149 for the treatment of chronic obstructive pulmonary disease (COPD). QVA149 is a combination of NVA237, a once-daily long-acting muscarinic antagonist (LAMA) and indacaterol, a once-daily long-acting beta-2 agonist (LABA).

The randomised, double-blind, placebo-controlled, multi-centre study will determine the effect of QVA149 and indacaterol on mean 24-hour heart rate in patients with moderate to severe COPD.

NVA237 was licensed to Novartis by Sosei and Vectura in 2005 in a deal in which the two companies could receive up to US$ 375 million in milestones as well as royalties on product sales. Indacaterol was discovered by Novartis and is currently in Phase III trials for COPD. NDA submissions have been projected for 2010.

Mr Shinichi Tamura, President & CEO of Sosei, said: "I am delighted that QVA149 has now entered Phase II clinical development. This once-daily LAMA/LABA combination has the potential to be a best in class treatment."

Dr Chris Blackwell, Chief Executive of Vectura added: "Chronic respiratory diseases like COPD are often sub-optimally treated, and patients don't always receive effective therapies. The market for COPD therapy is predicted to double in size to $11 billion by 2011. The progress Novartis is making with both NVA237 and QVA149 is therefore of interest to many."

Notes for Editors:

About the NVA237 licence agreement with Novartis

Sosei and its co-development partner Vectura Group plc concluded a global development and commercialisation agreement with Novartis in April 2005 for their collaborative product NVA237. Novartis is responsible for developing and commercializing NVA237 both as a monotherapy and in combination with indacaterol, its once daily, long acting beta 2 agonist, as QVA149.

Under the terms of the agreement, Sosei and Vectura have already received $15 million each and will receive up to $172.5 million each for achieving pre-agreed clinical, regulatory and commercialisation targets for both the monotherapy and combination product. These potential milestones thus total up to $375 million. In addition, royalties on product sales will be paid for the monotherapy and the combination product. If a third combination product is developed by Novartis, using NVA237, further milestones and royalties may be payable.

About COPD

COPD is a chronic obstruction of the airways which in the developed world is caused primarily by smoking. Symptoms include chronic bronchitis and/or emphysema which slowly progress and eventually lead to a largely irreversible loss of lung function. COPD is currently the fourth most common cause of death and by 2020 is predicted to become the third most common cause of death and the fourth most important disability causing illness. The total financial burden of lung disease in Europe amounts to nearly EUR102 billion with COPD contributing almost one half of this figure. Around three-quarters of patients with advanced COPD are unable to perform normal everyday activities.

The current market for COPD drug therapy is estimated to be worth around $6 billion per annum and is forecast to grow to $11 billion by 2011 as a result of increasing diagnosis and treatment and the growth of high value new products.

About Sosei

Sosei is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.

For further information about Sosei, please visit http://www.sosei.com

About Vectura

Vectura is a pulmonary drug development company focused principally on the development of a range of inhaled therapies for the treatment of respiratory and neurological diseases. The respiratory market is forecast to achieve sales of $32 billion by 2011. Vectura develops products to treat respiratory diseases such asthma, COPD and cystic fibrosis. Vectura also develops products where optimised delivery via the lungs into the blood stream can provide significant benefits, such as a rapid onset of action, improved efficacy and improved tolerability compared with current therapies.

Vectura has eight marketed products and a portfolio of drugs in clinical and pre-clinical development, some of which have been licensed to major pharmaceutical companies. The Company also seeks to develop certain programmes further through development to optimise value at a later licensing stage. Vectura also offers its formulation and inhalation technologies to other pharmaceutical companies on a licensing basis where this complements Vectura's business strategy.

Vectura has development collaborations with a broad range of pharmaceutical companies including Boehringer Ingelheim, Novartis, and Chiesi. The acquisition of Innovata in January 2007 brought established alliances with a number of additional companies, such as Baxter, GSK, Merck Generics (part of Mylan Inc), UCB and Otsuka as well providing revenue streams, complementary products and critical mass.

For further information, please visit Vectura's website at http://www.vectura.com


'/>"/>
SOURCE Sosei Group Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. National Association of Subrogation Professionals (NASP), the Largest Insurance Subrogation Association in the World - Announced Today that Leslie Wiernik has Joined the Organization as Director of Education
11. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... Qualis Health, one of the ... 8th Annual DecisionHealth Platinum Awards in recognition of its innovative healthcare management programs ... across multiple award categories, highlighting four of the organization’s current programs:, ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... operations executives and focusing on all facets of clinical trial planning and management. ... , patient engagement, and more. In addition, attendees stopping by Pharmica’s booth were ...
(Date:2/17/2017)... ... 2017 , ... Top neuroendocrine cancer doctors, nurses and specialists from around the ... - 23 in Beaver Creek, CO. It was announced today by Cindy Lovelace, executive ... Beaver Creek, hosting over 60 faculty members and addressing unmet needs of the NET ...
(Date:2/16/2017)... ... February 17, 2017 , ... ... last long after their final treatments. Physician researchers at The Marcus Institute ... a mind-body therapy, for efficacy in reducing symptoms of traumatic stress in cancer ...
(Date:2/16/2017)... ... February 16, 2017 , ... Doctors on Liens is proud ... their network through his work at BKP Chiropractic in Lancaster . ... degree from Canada’s prestigious International Baccalaureate Program, Dr. Raj went on to open ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... , February 17, 2017 Cryoablation, Electrical, ... The global ablation technologies market is expected to grow ... from 2022-2027. The market is expected to grow at a CAGR ... $3.3bn in 2016, and $9.05bn in 2026. ... How this report will benefit you ...
(Date:2/17/2017)... , February 17, 2017 According to ... Particle Counters, Liquid Particle Counters), Application (Cleanroom Monitoring, Contamination Monitoring of ... to 2021" published by MarketsandMarkets, the market is expected to reach ... at a CAGR of 3.7% from 2016 to 2021. ... ...
(Date:2/17/2017)... 17, 2017 Theravance Biopharma, Inc. (NASDAQ: ... "Company") today announced the presentation of positive clinical ... administered pan-Janus kinase (JAK) inhibitor designed to be ... of the European Crohn,s and Colitis Organization (ECCO). ... data from its completed Phase 1 study of ...
Breaking Medicine Technology: